Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date

CRANFORD, N.J., April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical... | April 24, 2023

Related Keywords

Texas ,United States ,India ,America ,Leonard Mazur ,Greg Salsburg ,Ilanit Allen ,Prnewswire Citius Pharmaceuticals Inc ,Infectious Diseases Society Of America ,Citius Pharmaceuticals Inc ,Securities Exchange ,University Of Texas Md Anderson Cancer Center ,Exchange Commission ,Company Nasdaq ,Infectious Diseases Society ,Citius Pharmaceuticals ,Fast Track ,Securities Act ,Securities Exchange Act ,Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Itius ,Iopharmaceutical ,Company ,Edicated ,O ,The ,Development ,End ,Ommercialization ,F Ctxr Us17322u2078 ,